-- uniQure N.V. (NASDAQ: QURE), a leader in human gene therapy, today announced that its Board of Directors has accepted the resignation of Daniel Soland as chief executive officer (CEO) and an executive member of the Board, effective immediately. The Board is pleased to announce that Matthew Kapusta, the Company's chief financial officer (CFO) since January 2015 who also serves as an executive member of the Board, has been appointed interim CEO